XML 128 R91.htm IDEA: XBRL DOCUMENT v3.21.2
Segments (Details)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jul. 03, 2021
USD ($)
Jun. 27, 2020
USD ($)
Jun. 27, 2020
USD ($)
Jul. 03, 2021
USD ($)
Jul. 03, 2021
USD ($)
Segment
Jun. 27, 2020
USD ($)
Jun. 27, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Segment Reporting Information [Line Items]                    
Number of reportable segments | Segment         2          
Depreciation and amortization $ (1,852) $ (1,813)   $ (3,777)   $ (3,638)        
Interest (expense) income (1,681) (2,834)   1,195   (5,215)        
Equity compensation (5,778)         (7,722)        
Acquisition and integration costs (1,833)       $ (5,029)          
Equity loss in unconsolidated investments 432       901          
Change in fair value of contingent consideration (641) 0   (641) (641) 0 $ 0      
Impairments related to variable interest entity (5,674) 0   (5,674)   0        
(Loss) income before income taxes (9,066) $ (6,090) $ (6,090) $ 15,389 15,389 $ 4,435 4,435      
Bio Ventus LLC                    
Segment Reporting Information [Line Items]                    
Depreciation and amortization               $ (7,439) $ (7,908) $ (8,615)
Interest (expense) income               (9,751) (21,579) (19,171)
Equity compensation               (10,103) (10,844) (14,325)
Restructuring costs               (563) (575) (1,373)
Change in fair value of contingent consideration                   739
(Loss) income before income taxes               15,914 9,689 6,107
Segment Reconciling Items                    
Segment Reporting Information [Line Items]                    
Depreciation and amortization (7,479)   (7,248)   (14,663)   (14,513)      
Interest (expense) income (1,681)   (2,834)   1,195   (5,215)      
Equity compensation (5,853)   (255)   16,559   6,771      
COVID-19 benefits, net     1,101       1,101      
Succession and transition charges (187)   (3,801)   (344)   (4,574)      
Foreign currency impact 12   46   64   (40)      
Acquisition and integration costs (1,833)       (5,029)          
Inventory step-up costs (2,106)       (2,106)          
Equity loss in unconsolidated investments (432)       (901)          
Change in fair value of contingent consideration (641)       (641)          
Impairments related to variable interest entity (7,043)       (7,043)          
Other non-recurring costs (1,710)   (41)   (2,659)   (283)      
Segment Reconciling Items | Bio Ventus LLC                    
Segment Reporting Information [Line Items]                    
Depreciation and amortization               (28,643) (30,316) (29,238)
Interest (expense) income               (9,751) (21,579) (19,171)
Equity compensation               (10,103) (10,844) (14,325)
COVID-19 benefits, net               4,123    
Succession and transition charges               (5,609)    
Restructuring costs               (563) (575) (1,373)
Foreign currency impact               117 (8) (234)
Equity loss in unconsolidated investments               (467)    
Other non-recurring costs               (5,633) (6,177) (1,723)
U.S | Operating Segments                    
Segment Reporting Information [Line Items]                    
Segment adjusted EBITDA 17,149   7,439   27,147   21,151      
U.S | Operating Segments | Bio Ventus LLC                    
Segment Reporting Information [Line Items]                    
Segment adjusted EBITDA               69,252 71,673 67,480
International Segment | Operating Segments                    
Segment Reporting Information [Line Items]                    
Segment adjusted EBITDA $ 2,738   $ (497)   $ 3,810   $ 37      
International Segment | Operating Segments | Bio Ventus LLC                    
Segment Reporting Information [Line Items]                    
Segment adjusted EBITDA               $ 3,191 $ 7,515 $ 4,691